INVESTOR INFORMATION

Where is Delcath's headquarters?

Delcath is headquartered in New York, NY. Our mailing address is:
1633 Broadway, 22nd Floor, Suite C
New York, NY 10019
Telephone: (212) 489-2100
Fax: (212) 489-2102

When was Delcath founded?

Delcath was founded in 1988.

Where is Delcath incorporated?

Delcath is incorporated in Delaware.

What is Delcath’s fiscal year?

Delcath’s fiscal year ends on December 31.  

FINANCIAL / SHAREHOLDER INFORMATION

On which exchange is Delcath listed and what is the ticker symbol?

Delcath is quoted on the NASDAQ Capital Market under the ticker symbol DCTH.

In what year did Delcath go public?

Delcath began trading on the NASDAQ under the ticker symbol DCTH on October 22, 2001.

Who do I contact regarding lost stock certificates, address changes, and changes of ownership or name in which shares are held?

Please contact Delcath’s transfer agent, American Stock Transfer and Trust Company, LLC
6201 15th Ave.
Brooklyn, NY 11219
1-800-937-5449
www.amstock.com

What is the stock’s CUSIP number?

The CUSIP number is 24661P.

Can I purchase stock directly from Delcath?

Delcath does not have a direct purchase program. You must purchase stock through your broker.

Has Delcath had any stock splits?

Since our initial public offering in 2000, we have effected five reverse stock splits. The last two splits were a one-for-five hundred (1:500) reverse stock split effected on May 2, 2018, and a one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019.

Has Delcath repurchased any stock?

Delcath has not repurchased any stock.

What is Delcath's policy on dividends and dividend reinvestment plans?

Delcath has never paid any cash dividends on our common stock and we do not anticipate paying cash dividends in the foreseeable future and will subsequently not propose a dividend reinvestment plan. Delcath believes in reinvesting in research & development, the key driver of future growth for the company.

Who are Delcath's independent auditors?

Our independent auditors are Marcum LLP.  

CORPORATE GOVERNANCE INFORMATION

Where can I get information on Delcath’s Corporate Governance practices?

Please visit the following section of our website to read our corporate governance guidelines.

How can I contact Delcath’s Board of Directors?

Any stockholder wishing to communicate with the board or with any specified director should address their communication to the board of directors or to the particular director(s) in care of: Corporate Secretary, Delcath Systems, Inc., 1633 Broadway, 22nd Floor, Suite C, New York, NY 10019. Please use this mail address to contact the board of directors for legitimate business inquiries only. Solicitations of any kind will be discarded.

How many members of Delcath’s board of directors are independent under SEC standards?

The board has determined that a majority of our incumbent directors –Roger Stoll, Elizabeth Czerepak, Steve Salamon, Gil Aharon and John Sylvester – are “independent” directors within the definition of NASDAQ rules.

Is the chair of Delcath’s audit committee independent?
Yes. The audit committee is led by Elizabeth Czerepak.

Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.